Home | Careers | BI | Contact us


Neopharm Group Acquires Fresenius Biotech

March 3, 2014

Neopharm Group, owned by the Fuhrer family, acquired Fresenius Biotech, a subsidiary of Fresenius SE & Co. KGaA….

סופרברנד 2012

Advil – a Superbrand in Israel

December 25, 2012

2012 marks the third year Advil has won “Superbrand” status in the healthcare arena in Israel. This…

Eisai’s Halaven® Approved In Israel

July 12, 2012

 HATFIELD, UK 10 July 2012 – Halaven® (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has recently received…

Sativex® receives regulatory approval in Israel

June 13, 2012

Neopharm Group and GW Pharmaceuticals plc announced that Sativex® (Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) oromucosal spray) has received regulatory approval from the Israeli Ministry of Health for the treatment of spasticity and neuropathic pain due…

← Previous PageNext Page →

Home | About Us | Companies | Partnering | Research | Corporate Citizenship | Careers | Newsroom | Contact | Legal Notice

All Rights reserved, Neopharm Group, Israel | Design by: VAZA | Developed by: The Shark Lady